Incidence

Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022

Retrieved on: 
Wednesday, May 4, 2022
Oncology, Medical Devices, Health, Genetics, General Health, Biotechnology, Consensus, Laboratory, European Society for Medical Oncology, Forward-looking statement, Division, Oncology, University, Breast cancer, Decision-making, Twitter, NanoString Technologies, Drug development, Woman, Health, Compte rendu, Physician, GEP, ESMO, Patient, Lymph, Diagnosis, Annual report, Incidence, European Institute, Delphi, Investor, Consensus decision-making, Disease, Education, European Institute of Oncology, SEC, University of Milano-Bicocca, Cancer, Recurrence, IRCCS, Medical imaging, Dietary supplement, Pharmaceutical industry

The findings, from the PROCURE study, were presented today at the European Society of Medical Oncology (ESMO) Breast Cancer 2022, taking place May 3-5 in Berlin, Germany.

Key Points: 
  • The findings, from the PROCURE study, were presented today at the European Society of Medical Oncology (ESMO) Breast Cancer 2022, taking place May 3-5 in Berlin, Germany.
  • The PROCURE study utilized Delphi methodology to generate consensus regarding the clinical utility of GEP tests, including Veracytes Prosigna Breast Cancer Assay, in breast cancer treatment.
  • A scientific committee of eight breast cancer experts developed a questionnaire, which was used to survey 133 specialists from 11 European countries.
  • We believe the PROCURE study will provide much-needed clarity to breast cancer clinicians and their patients about the clinical utility of GEP testing, Kelly Marcom, M.D., Veracytes medical director for breast cancer.

Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial

Retrieved on: 
Wednesday, May 4, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, ASCO, Warning, Creatinine, Orphan, Death, Food, Safety, Bile, Radiation, Pneumonitis, BTC, Patient, Infection, Gallbladder, Cisplatin, FDA, Food and Drug Administration Amendments Act of 2007, Incidence, Prednisone, Administration, Prescription Drug User Fee Act, Society, AstraZeneca, News, HIV disease progression rates, Priority review, Risk, HR, Medical imaging, Pharmaceutical industry, Vaccine, Durvalumab

AstraZenecas supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer (BTC).

Key Points: 
  • AstraZenecas supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer (BTC).
  • An estimated one in four (25%) patients treated with Imfinzi plus chemotherapy were alive at two years compared to one in 10 (10%) treated with chemotherapy alone.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • In 2021, updated results from the CASPIAN trial showed Imfinzi plus chemotherapy tripled patient survival at three years versus chemotherapy alone.

Johnson & Johnson Vision Named a Winner of Fast Company's 2022 World Changing Ideas Awards for ACUVUE® Theravision™ with Ketotifen

Retrieved on: 
Wednesday, May 4, 2022
ACUVUE, Nursing, Lake, Health, Water, Lens, Mouth, Health care, Medicine, Eye care professional, Eye, Smoker, Time, Infection, Abnormality, Diuretic, Ketotifen, Swimming, Conjunctiva, Incidence, Motion sickness, Dry, Severe cognitive impairment, List, Cornea, Visual acuity, Saliva, Eyelid, Lens (anatomy), Injury, Solution, Awareness, THE, Corneal ulcer, Risk, Presbyopia, Camera, Telescopic sight, Personal protective equipment, Cosmetics, Inspection, Abrasive

JACKSONVILLE, Fla., May 4, 2022 /PRNewswire/ -- Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson MedTech Companies†, was recognized as the winner of Fast Company's 2022 World Changing Ideas Awards in the Wellness category for ACUVUE® Theravision™ with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen). Each lens contains 19 mcg ketotifen. Fast Company also selected ACUVUE® Theravision™ with Ketotifen for an honorable mention in both the Health and Enduring Impact: 15+ Years in Business categories.

Key Points: 
  • At Johnson & Johnson Vision, part of Johnson & Johnson Medical Devices Companies, we have a bold ambition: to change the trajectory of eye health around the world.
  • *Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
  • The Johnson & Johnson MedTech Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson's MedTech segment.
  • Peter Menziuso is an employee of Johnson & Johnson Vision, Inc. with oversight as the Company Group Chairman of the Vision Care organization.

The Worldwide Opioids Industry is Expected to Reach $6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 4, 2022
Alternative Medicine, Pharmaceutical, Health, Analgesic, Morphine, Back pain, Codeine, Pain management, Pain, Methadone, Neuropathic pain, Cannabis, Cancer pain, Lists of countries and territories, Diarrhea, Patient, Oxycodone, Fentanyl, Cancer, Incidence, Cough, Hydrocodone, Chronic pain, CAGR, Growth, Migraine, Poultry

The global opioids market was valued at $4,412.48 million in 2020, and is projected to reach $6,060.17 million by 2030, registering a CAGR of 3.2% from 2021 to 2030.

Key Points: 
  • The global opioids market was valued at $4,412.48 million in 2020, and is projected to reach $6,060.17 million by 2030, registering a CAGR of 3.2% from 2021 to 2030.
  • Prescription opioids are primarily used to treat moderate to severe pain, while some opioids can be used to alleviate coughing and diarrhea.
  • The growth of the global opioids market is driven by alarming increase in incidence of orthopedic diseases & chronic pain.
  • Furthermore, rise in disposable income and surge in geriatric population are expected to propel the growth of the global opioids market.

The Worldwide Implantable Defibrillators Industry is Expected to Reach $5.6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 4, 2022
Medical Devices, Health, Atrial fibrillation, Arrhythmia, Insurance, MRI, Infarction, Ventricular tachycardia, Ventricular fibrillation, Implantable cardioverter-defibrillator, Abdomen, ICD, Patient, Electrode, Incidence, ICDS, History, Skin, Arrest, Magnetic resonance imaging, Palpitations, CAGR, SCA, Boston Scientific, Technology, Heart, Growth, Ventricular septal defect, Heart rate, Medical device

The "Implantable Defibrillators Market: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Implantable Defibrillators Market: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global implantable defibrillators market was valued at $3,300.00 million in 2020, and is projected to reach $5,612.62 million by 2030, registering a CAGR of 5.3% from 2021 to 2030.
  • Implantable defibrillators are battery-powered small devices placed underneath the chest or abdomen to keep track of a patient's heart rate.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market

Global Medical Radiation Detection, Monitoring & Safety Market Forecast to 2027: Increasing Prevalence of Cancer and Growing Geriatric Patient Population to Drive Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 4, 2022
Biotechnology, Radiology, Health, COVID-19, Globe, Solid, Electronic personal dosimeter, Prevalence, Monitoring, Cancer, Incidence, Hospital, Adoption, Radio, CAGR, Growth, Region, USD, Medical imaging, Scintillator, Safety

The gas-filled detectors segment accounted for the highest growth rate in the medical radiation detection, monitoring, & safety market, by detector type, during the forecast period

Key Points: 
  • The gas-filled detectors segment accounted for the highest growth rate in the medical radiation detection, monitoring, & safety market, by detector type, during the forecast period
    The medical radiation detection, monitoring, & safety market is segmented into gas-filled detectors, solid-state detectors, and scintillators based on type of detector.
  • Based on end users the medical radiation detection, monitoring, & safety market is segmented into hospitals and non-hospitals.
  • In 2021, the hospitals segment accounted for the largest share of the medical radiation detection, monitoring, & safety market.
  • COVID-19 Impact on the Medical Radiation Detection, Monitoring and Safety Market

Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, May 4, 2022
Biotechnology, Other Health, Health, Stem Cells, Pharmaceutical, COVID-19, U.S. Securities and Exchange Commission, Graft-versus-host disease, Investment, David Berry (inventor), Private Securities Litigation Reform Act, University, Ulcerative colitis, File, Nasdaq, Company, Food, Safety, Research, Hematopoietic stem cell transplantation, Patient, BLA, Security (finance), Trial of the century, The New England Journal of Medicine, Clostridioides difficile infection, Infection, Program, FDA, Annual report, NEJM, Therapy, Chicago (franchise), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Incidence, CDI, Variometer, Tissue, Adult, Death, Medical Affairs Bureau, Disease, Bloodstream infections, SEC, Gastrointestinal tract, Growth, Memorial Sloan Kettering Cancer Center, Recurrence, Antibiotics, Pharmaceutical industry, Serica, UC

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates.
  • Seres continues to execute pre-commercialization activities in collaboration with Aimmune Therapeutics, including market education and data dissemination to the medical community.
  • Seres ended the first quarter of 2022 with approximately $248.0 million in cash, cash equivalents and investments as compared with $291.2 million at the end of 2021.
  • To access the conference call, please dial 877-270-2148 (domestic) or 412-902-6510 (international) and reference the Seres Therapeutics conference call.

Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives

Retrieved on: 
Tuesday, May 3, 2022
Research, Philanthropy, Biotechnology, Other Health, Health, Fund Raising, Foundation, Science, Oncology, COVID-19, Skin Cancer Foundation, Clothing, Skin cancer, Australian Melanoma Research Foundation, Instagram, Twitter, Nasdaq, List of life sciences, Health, DecisionDx-UM, Company, Securities Exchange Act of 1934, Securities Act of 1933, Physician, Patient, Foundation, Atopic dermatitis, Partnership, Organization, Cancer, Diagnosis, Incidence, Annual report, MRF, LinkedIn, Disease, TikTok, Uveal melanoma, Education, Skin, Awareness, SEC, Research, Pharmaceutical industry, Medical imaging, Melanoma, Facebook

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its ongoing collaboration with the Melanoma Research Foundation (MRF) and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its ongoing collaboration with the Melanoma Research Foundation (MRF) and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month.
  • Skin cancer is the most common form of cancer in the U.S., and its incidence continues to rise.
  • MRF and The Skin Cancer Foundation are making fantastic strides in their advocacy efforts on behalf of the skin cancer patient community, and we are proud to support their efforts.
  • Proceeds from this event, in which Castle is a sponsor, support the Foundations educational campaigns, community programs and research initiatives.

Arizona-Based School of Ultrasound Creates Career Opportunities While Boosting Heart Health

Retrieved on: 
Tuesday, May 3, 2022
COVID-19, School, Population, STEM, JAMA, Diet, Employment, Infarction, Student, CCI, Woman, Health, Death, Stroke, Heart, RVS, Cardiovascular disease, RCS, Foundation, Certification, Blood, American Medical Association, Program, Diagnosis, Incidence, Hospital, Journal, Workforce, Retirement, Multimedia, Banner Health, Education, Ageing, Solution, National Heart Foundation of Australia, CEO, Research, FICO, Arizona Heart Institute, Man, Risk, Exercise, Medicine, Medical imaging, Merit pay, MD

PHOENIX, May 3, 2022 /PRNewswire/ -- The Arizona Heart Foundation, a nonprofit organization committed to fighting cardiovascular disease through professional education and public awareness, is offering a financing option that increases access to education for careers in cardiovascular health care. Through a collaboration with Meritize, a pioneer in financing solutions for skills-based education and training, the Foundation's School of Cardiac & Vascular Ultrasound has helped more than 80 aspiring health care professionals access financing needed to complete the education required to become a cardiac or vascular sonographer.

Key Points: 
  • "By making the financing for our educational programs more accessible, we can tackle the shortage of skilled health talent in our region.
  • Expanding access to acquiring skills and education is essential for improving the quality of cardiovascular health diagnosis, prevention and treatment."
  • Through an intensive 12-month program, the Arizona Heart Foundation's School of Cardiac & Vascular Ultrasound training includes 6 months in the classroom, followed by 6 months of hands-on time next to a lead sonographer.
  • In addition to its educational programs, the Arizona Heart Foundation, through its 2022 Cardiovascular Initiative, offers complimentary ultrasound scans across Arizona.

impact.com Announces Continued Growth in First Quarter of 2022, Demonstrating Strong Demand for Its Innovative Technology Supporting Brands, Publishers, Agencies and Channel Partners in the Thriving Partnership Economy

Retrieved on: 
Tuesday, May 3, 2022
Technology, Publishing, Public Relations, Investor Relations, Advertising, Communications, Software, Social Media, Data Management, Search Engine Marketing, Compliance, Trust, Ecosystem, Prevalence, PXA, Certification, Partnership, Fanaticism, Associate, Golden Drum Award, Acquisition, Walmart, Incidence, Knowledge, Commerce, Leadership, Workflow, Advertising, Marketing, Supernode, Technology, Research, Providence Public Library, Chief executive officer, Martech, IPX, Awareness, Pressboard, Uber, Video game, Cryptocurrency, Lenovo, Shopify, Industry

The growth impact.com continues to see is a result of the strong demand for innovative technology that brands and partners require to remain competitive, scale revenue, and become more relevant in the daily lives of the modern customer.

Key Points: 
  • The growth impact.com continues to see is a result of the strong demand for innovative technology that brands and partners require to remain competitive, scale revenue, and become more relevant in the daily lives of the modern customer.
  • The partnership economy is accelerating as more businesses recognize the immense value in partnering with these sources of commerce content: influencers, creators, large media publishers, affiliates, businesses, and other channel partners.
  • As the advertising industry evolves, so does consumer adoption of - and attitudes towards - various advertising tactics, so publishers need to adapt.
  • Additional highlights from the quarter include:
    Announced strategic secondary investment of approximately $100 million from W Capital Partners (W Capital) and Providence Public.